Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGMS2 | Q8NHU3 | 5/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | PARP1 | P09874 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.51 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6562177 | 0.85 | HTT (0.60) | SGMS2NPC1HTTGAAPARP1 | |
| SCHEMBL2999130 | 0.85 | SGMS2 (0.59) | SGMS2NPC1HTTGAAPARP1 | |
| SCHEMBL30194507 | 0.85 | SGMS2 (0.59) | SGMS2NPC1HTTGAAPARP1 | |
| SCHEMBL14339650 | 0.85 | SGMS2 (0.59) | SGMS2NPC1HTTGAAPARP1 | |
| SCHEMBL19156329 | 0.85 | SGMS2 (0.59) | SGMS2NPC1HTTGAAPARP1 | |
| SCHEMBL4431127 | 0.85 | SGMS2 (0.59) | SGMS2NPC1HTTGAAPARP1 | |
| SCHEMBL6243854 | 0.85 | NPC1 (0.64) | SGMS2NPC1HTTGAAPARP1 | |
| SCHEMBL7344495 | 0.85 | SGMS2 (0.59) | SGMS2NPC1HTTGAAPARP1 | |
| SCHEMBL4944383 | 0.85 | NPC1 (0.60) | SGMS2NPC1HTTGAAPARP1 | |
| SCHEMBL3674806 | 0.84 | MAOB (0.62) | NPC1MEN1KMT2ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048920-A1 | Preparation of (+)-Catechin, (-)-Epicatechin, (-)-Catechin, and (+)-Epicatechin and Their 5,7,3',4'-Tetra-O-Benzyl Analogues | MARS, INCORPORATED (US) | 2010-02-25 | — | — | US | disclosed |
| CN-101248057-A | Preparation of (+) -catechin, (-) -epicatechin, (-) -catechin, (+) -epicatechin, and their 5, 7, 3 ', 4' -tetra-O-benzyl analogues | MARS INC (US) | 2008-08-20 | — | — | CN | disclosed |
| EP-1896443-A1 | PREPARATION OF (+)-CATECHIN, (-)-EPICATECHIN, (-)-CATECHIN, (+)-EPICATECHIN, AND THEIR 5,7,3',4'-TETRA-O-BENZYL ANALOGUES | MARS, INCORPORATED (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2007002877-A1 | PREPARATION OF (+)-CATECHIN, (-)-EPICATECHIN, (-)-CATECHIN, (+)-EPICATECHIN, AND THEIR 5,7,3',4'-TETRA-O-BENZYL ANALOGUES | MARS, INCORPORATED (US) | 2007-01-04 | — | — | WO | disclosed |
| EP-1071670-B1 | NOVEL DIPHENYL-SUBSTITUTED 5-RING-HETEROCYCLES, METHOD FOR PRODUCING THEM AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2004-07-07 | — | — | EP | disclosed |
| EP-0968202-B1 | Process for preparing photoactive coumarin dervatives | CLARIANT FINANCE BVI LTD (VG) | 2002-07-03 | — | — | EP | disclosed |
| EP-0977747-B1 | PHOTOACTIVE COUMARIN DERIVATIVES | CLARIANT FINANCE BVI LTD (VG) | 2002-06-12 | — | — | EP | disclosed |
| US-6255327-B1 | ANTIHYPOXC, ANTIISCHEMIC AGENTS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-07-03 | — | — | US | disclosed |
| EP-1071670-A1 | NOVEL DIPHENYL-SUBSTITUTED 5-RING-HETEROCYCLES, METHOD FOR PRODUCING THEM AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM KG (DE) | 2001-01-31 | — | — | EP | disclosed |
| CN-1254338-A | Process for preparing photoactive coumarin derivatives | HOECHST CELANESE CORP (CH) | 2000-05-24 | — | — | CN | disclosed |
| CN-1251584-A | Photoactive coumarin derivatives | HOECHST CELANESE INTERNATIONAL (CH) | 2000-04-26 | — | — | CN | disclosed |
| EP-0977747-A1 | PHOTOACTIVE COUMARIN DERIVATIVES | CLARIANT INTERNATIONAL LTD. (CH) | 2000-02-09 | — | — | EP | disclosed |
| EP-0968202-A1 | PROCESS FOR PREPARING PHOTOACTIVE COUMARIN DERIVATIVES | CLARIANT INTERNATIONAL LTD. (CH) | 2000-01-05 | — | — | EP | disclosed |
| WO-1999054314-A1 | NOVEL DIPHENYL-SUBSTITUTED 5-RING-HETEROCYCLES, METHOD FOR PRODUCING THEM AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 1999-10-28 | — | — | WO | disclosed |
| WO-1998039317-A1 | PROCESS FOR PREPARING PHOTOACTIVE COUMARIN DERIVATIVES | CLARIANT INTERNATIONAL LTD. (CH) | 1998-09-11 | — | — | WO | disclosed |
| WO-1998039319-A1 | PHOTOACTIVE COUMARIN DERIVATIVES | CLARIANT INTERNATIONAL LTD. (CH) | 1998-09-11 | — | — | WO | disclosed |
| US-5703075-A | Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones | PHARMACIA & UPJOHN COMPANY (US) | 1997-12-30 | — | — | US | disclosed |
| US-5144029-A | Calcium antagonist | DELALANDE S.A. (FR) | 1992-09-01 | — | — | US | disclosed |
| EP-0459983-A1 | ANTIATHEROSCLEROTIC AND ANTITHROMBOTIC 1-BENZOPYRAN-4-ONES AND 2-AMINO-1,3-BENZOXAZINE-4-ONES | PHARMACIA & UPJOHN COMPANY (US) | 1991-12-11 | — | — | EP | disclosed |
| WO-1990006921-A1 | ANTIATHEROSCLEROTIC AND ANTITHROMBOTIC 1-BENZOPYRAN-4-ONES AND 2-AMINO-1,3-BENZOXAZINE-4-ONES | THE UPJOHN COMPANY (US) | 1990-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048920-A1 | Preparation of (+)-Catechin, (-)-Epicatechin, (-)-Catechin, and (+)-Epicatechin and Their 5,7,3',4'-Tetra-O-Benzyl Analogues | HAAO, TES, HPD | SGMS2 2976/4885NPC1 3536/4885HTT 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.